Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide
Authors:
Open Access
- 6 October 2023
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-14
Abstract
Background: Glioblastoma (GB) is the most aggressive of all primary brain tumours and due to its highly invasive nature, surgical resection is nearly impossible. Patients typically rely on radiotherapy with concurrent temozolomide (TMZ) treatment and face a median survival of ~ 14 months. Alterations in the Epidermal Growth Factor Receptor gene (EGFR) are common in GB tumours, but therapies targeting EGFR have not shown significant clinical efficacy. Methods: Here, we investigated the influence of the EGFR regulatory genome on GB cells and identified novel EGFR enhancers located near the GB-associated SNP rs723527. We used CRISPR/Cas9-based approaches to target the EGFR enhancer regions, generating multiple modified GB cell lines, which enabled us to study the functional response to enhancer perturbation. Results: Epigenomic perturbation of the EGFR regulatory region decreases EGFR expression and reduces the proliferative and invasive capacity of glioblastoma cells, which also undergo a metabolic reprogramming in favour of mitochondrial respiration and present increased apoptosis. Moreover, EGFR enhancer-perturbation increases the sensitivity of GB cells to TMZ, the first-choice chemotherapeutic agent to treat glioblastoma. Conclusions: Our findings demonstrate how epigenomic perturbation of EGFR enhancers can ameliorate the aggressiveness of glioblastoma cells and enhance the efficacy of TMZ treatment. This study demonstrates how CRISPR/Cas9-based perturbation of enhancers can be used to modulate the expression of key cancer genes, which can help improve the effectiveness of existing cancer treatments and potentially the prognosis of difficult-to-treat cancers such as glioblastoma.Keywords
Funding Information
- Cancerforskningsfonden i Norrland (AMP 22-1091, AMP 23-1137, AMP 19-977, LP 21-2290)
- Knut och Alice Wallenbergs Stiftelse (WCMM Umeå)
- Vetenskapsrådet (2019-01960)
- Cancerfonden (21 1720)
- Kempestiftelserna (SMK-1964.2)
- Umea University
This publication has 36 references indexed in Scilit:
- The Warburg Effect: How Does it Benefit Cancer Cells?Trends in Biochemical Sciences, 2016
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for GlioblastomaJAMA, 2015
- Gene regulation during development in the light of topologically associating domainsWIREs Developmental Biology, 2015
- Reactive Oxygen Species and Apoptosis2014
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in GlioblastomasAmerican Journal of Surgical Pathology, 2012
- Chemotaxis in cancerNature Reviews Cancer, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- ber den Stoffwechsel der CarcinomzelleThe Science of Nature, 1924